Versican Plus DHPPi
canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus
Table of contents
Overview
This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Versican Plus DHPPi
|
Agency product number |
EMEA/V/C/003679
|
Active substance |
canine distemper virus, strain CDV Bio 11/A, canine adenovirus type 2, strain CAV-2 Bio 13, canine parvovirus type 2b, strain CPV-2b Bio 12/B and canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 (all live attenuated)
|
International non-proprietary name (INN) or common name |
canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI07AD04
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
03/07/2014
|
Contact address |
Rue Laid Burniat 1 |
Product information
17/04/2019 Versican Plus DHPPi - EMEA/V/C/003679 - IB/0014
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for canidae
-
Live viral vaccines
Therapeutic indication
Active immunisation of dogs from six weeks of age.
- to prevent mortality and clinical signs caused by canine distemper virus,
- to prevent mortality and clinical signs caused by canine adenovirus type 1,
- to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,
- to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus,
to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus.